---
title: A Model for the Application of Target-Cont - Andrew R. Gallimore
author: Andrew R. Gallimore
tags:
  - book
cover: _resources/books/A Model for the Application of Target-Cont - Andrew R. Gallimore/cover.jpeg
---


    
        
        
        Cover
        
            @page {padding: 0pt; margin:0pt}
            body { text-align: center; padding:0pt; margin: 0pt; }
        
    
    
        
            
                
            
        
    

        

# Document Outline

- A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience]]
    - Introduction]]
    - Methods and Results]]
    - Discussion]]
    - Author Contributions]]
    - Funding]]
    - References]]Gal imore and Strassman

Target-Control ed IV DMT Infusion

in humans is well-established (Barker et al., 2012)]], although the by bolus injection (Strassman et al., 1996)]] makes it biological significance of this remains to be elucidated. DMT is unique among classic serotonergic psychedelics: e.g., LSD

actively transported across the blood brain barrier in rats and

(Belleville et al., 1956)]]. This property renders DMT amenable dogs (Sangiah et al., 1979; Takahashi et al., 1985;]] Yanai et al.,]]

to

administration

by

continuous

intravenous

infusion,

1986)]], and a similar mechanism plausibly exists in humans. DMT

in which the drug is administered at a predetermined is also a substrate for the human serotonin and monoamine rate over a period of time and subjective effects can be vesicular transporters (Cozzi et al., 2009)]]. The key enzyme for prolonged.

its production, indolethylamine N-methyltransferase, has been

Gouzoulis-Mayfrank et al. (2005)]] used such an approach detected in the brain, pineal gland, and retina of primates (Cozzi to study the psychological effects of both DMT and ketamine.

et al., 2011)]]. Taken together, these data suggest that DMT may This group’s infusion rates were established by observing the have a significant role in human neurophysiology, consciousness, subjective effects of the drug, rather than taking into account its and the visual system.

underlying pharmacokinetics or pharmacodynamics. That three Clinical psychedelic drug research has resumed after a of the 15 subjects dropped out of the study because of adverse generation’s hiatus, and its scope is expanding rapidly. Modern psychological reactions suggests that this model resulted in an functional neuroimaging techniques are revealing the neural overly high infusion rate. A more pharmacokinetically-informed accompaniment of these altered states of consciousness approach to infusion will allow the attainment and maintenance

(Vollenweider et al., 1997;]] Carhart-Harris et al., 2012;]] Roseman of a stable blood—and presumably brain—concentration of et al., 2014; Tagliazucchi et al., 2014; Gallimore, 2015; Nichols,]]

DMT, and thus provide a safe and effective prolonged immersion

2016)]]. However, comparable thoroughgoing analyses of their in the unique DMT state.

phenomenology are lacking. This is surprising because of how unusual and highly replicable are the subjective effects of the psychedelic drugs in general, in particular those of DMT. The METHODS AND RESULTS

profound and easily reproducible effects of DMT and other psychedelics may provide valuable insights into the structure of Target-controlled intravenous infusion is a methodology the human mind—the central focus of psychology itself. As such, developed for use in general anesthesia, during which it is in addition to their neural correlates, the phenomenology and essential that the concentration of drug at the target site (the content of the DMT state calls for rigorous academic enquiry.

brain) be established and stably maintained (Kenny and White,]]

Studies of DMT in humans began in the 1950s (Boszormenyi

1990;]] Absalom et al., 2016)]]. If drug levels drop too low, the and Szara, 1958;]] Sai-Halasz et al., 1958; Szara, 2007;]] Gallimore patient may rouse during the procedure, and rising brain levels and Luke, 2015)]], when its mind-altering effects were explored as may result in potentially life-threatening effects. Computer-a form of chemically-induced psychosis. However, such studies assisted infusion devices are now routinely used to ensure simply classified the complex visual effects as “hallucinations”

anesthetic levels remain within the required therapeutic window.

with no further analysis. Neither do most modern studies The foundation of these systems is a mathematical model of purporting to examine the psychological effects of psychedelic the pharmacokinetics and pharmacodynamics of the anesthetic drugs routinely provide detailed descriptions of the altered state drug (Gambus and Troconiz, 2015)]]. For a drug to be suitable

(Riba et al., 2001; Gouzoulis-Mayfrank et al., 2005)]]. An exception for target-controlled infusion it should ideally possess a number is the largest clinical study of DMT to date, which paid careful of characteristics listed in **Table 1**]] (Miller, 1994)]]. Fortunately, attention to the content of the DMT experiences of nearly five the water-soluble DMT salt used for intravenous administration dozen volunteers administered a wide range of DMT doses meets all of these criteria.

(Strassman et al., 1994; Strassman, 1995, 2001)]].

As a drug is introduced into the body by intravenous The time course of DMT administered via inhalation of injection, it is rapidly diluted and distributed by the blood.

vaporized freebase or intravenous injection of a water-soluble It also equilibrates to various degrees with peripheral salt is brief. The onset is rapid and overwhelming, with tissues—dependent on specific drug properties and degree full effects noted within 2 min of administration. Subjective of vascularization of the relevant tissues—and with the effect effects are usually fully resolved within 20–30 min. A powerful site itself. The elimination of the drug from the body also begins

“rush” heralds the effect of a fully psychedelic dose of DMT, immediately, by a combination of enzymatic transformation, marked by a sense of tremendous acceleration and psychic and urinary and/or biliary excretion. Pharmacokinetic models and somatic tension. These culminate in the dissociation of must take into account both intrinsic and drug-specific factors consciousness from bodily awareness and entry into a “world that affect drug absorption, distribution, and elimination. Single-of light” characterized by extremely complex visions. Users compartment models only consider the rapid dilution of the frequently report the sense of receiving “information,” as well drug in the main vascular compartment, whereas two- and three-as the conviction that what is being observed feels as if it compartment models also take into account equilibration of were an autonomous alternate world rather than a dream or the drug with peripheral tissues. The pharmacokinetics of most hallucination. A commonly heard refrain is that the experience anesthetics are best fitted to either a two- or three-compartment was “more real than real.”

model (Shafer and Gregg, 1992)]]. Since DMT turns out to be best The inability to induce psychological tolerance to repeated fitted to a two-compartment model (see later), only this type will full-psychedelic doses of intravenous DMT administered be described here (**Figure 1**)]].

Frontiers in Pharmacology]] | www.frontiersin.org]]

2

 Article 211]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

TABLE 1 | Desired characteristics of drugs for continuous IV infusion subjects were used in the analysis (9 sets each of 0.4 and 0.2 mg/kg

(Miller, 1994)]].

time series data).

These time-series data were fitted to one-, two-, and three-1. Water-soluble

compartment pharmacokinetic models. The naïve averaged data 2. Rapid onset of action

approach is the most straightforward technique for fitting 3. Short duration of effect

pharmacokinetic data, in which plasma concentration at each 4. Lack of tolerance

time point is averaged over all subjects to generate a mean dose-5. High clearance rate with minimal tendency for accumulation response curve. This curve is then fitted to a pharmacokinetic 6. No active metabolites

model. However, methods taking into account both fixed and 7. High therapeutic index

random effects on the dose-response—for example, non-linear 8. Minimal side-effects

mixed effects modeling (NON-MEM)—often give more reliable parameter estimates. These methods also allow identification of parameter covariates, such as weight or age (Mould and Upton,]]

Drug is introduced into the central compartment to rapidly

2012)]].

achieve a plasma concentration, CT, dependent on the volume Using the Matlab Simbiology toolkit (Mathworks, Inc.), of distribution, VC. The drug is removed from the central we fitted the 0.2 and 0.4 mg/kg time- series data separately.

compartment, quantified by a drop in plasma concentration Both datasets were best fitted to a two-compartment model over time, by both elimination and equilibration with the with enzymatic clearance, consistent with Michaelis-Menten peripheral compartment. This rate of plasma concentration kinetics (**Figure 2**)]]. This comports with the well-established rapid decline is controlled by the elimination rate constant, k10, and metabolism of DMT by monoamine oxidase (MAO) A (Barker the relative rates of movement from the central to the peripheral et al., 1980;]] Sitaram et al., 1987; Riba et al., 2015)]]. **Table 2**]] shows compartment, k12, and in the opposite direction, k21. The overall the population parameter estimates obtained.

rate, RT, obeys the differential equation:

These parameter estimates are for an “average” individual (i.e., obtained from the mean plasma concentration across R

the nine subjects at each time point), although the dose-T = CT × VC

k10 + k12e−k21 t

concentration response varied considerably among subjects. The Complete equilibration with the peripheral compartment is mean coefficients of variation in plasma DMT concentration, reflected in the exponential term decaying to zero and the steady between 2 and 30 min post-infusion, across the 0.2 and 0.4 mg/kg state elimination rate, R

groups were 83 and 58%, respectively. There was also variation in SS, is:

the estimated parameters depending on the dose. Since 0.4 mg/kg R

was the most reliable dose for inducing the fully psychedelic SS = CT × VCk10

DMT experience, we sought an infusion model that reaches Transfer from the central compartment to the effect site, R

and maintains the effect site concentrations observed with this 1E, is

generally modeled as a first-order process with rate constant, k dose. Therefore, the 0.4 mg/kg parameter set was chosen for 1e:

development of the infusion model. However, comparable results R1E = CTk1e

were obtained using the alternative parameter set.

Having established the model parameters, we then sought to To maintain a constant plasma, and thus effect site, extend the model to include the effect site (brain) concentration.

concentration, the infusion rate must equal the overall removal The model was simulated using an infusion protocol employed rate, RT. Since this is not constant, except at steady state, the in the original study (i.e., 0.4 mg/kg infusion over 30 s). While infusion rate must be adjusted to approximate the decline subjects were unable to communicate during the peak DMT

in RT over time. This requires the determination of the effects, a number of observations indicated that these peak pharmacokinetic parameters: VC, k10, k12, and k21, which can effects in each subject occurred at approximately 3 min from be achieved by fitting time-series blood sampling data to a the beginning of the infusion. First, the lower doses of drug pharmacokinetic model.

(0.05 and 0.1 mg/kg) were not incapacitating, and provided the To establish that the pharmacokinetics of DMT make it opportunity for volunteers to describe the onset, peak, and suitable for target-controlled infusion, we used DMT plasma dissipation of drug effects in a running commentary narrative concentration data from a previous study (Strassman and Qualls,]]

as they were occurring. With these lower doses, effects peaked

1994)]]. The details are provided in the original paper. Briefly, at approximately 3 min, began dissipating quickly, and were each subject receiving a “fully psychedelic” dose of DMT was resolved by 15–20 min. That the time course of peak DMT blood administered either 0.2 or 0.4 mg/kg DMT fumarate over 30 s levels is identical across the spectrum of doses suggests that the through an indwelling forearm intravenous catheter, followed correspondence between the time course of peak DMT effects by a 15 s flush with sterile saline. Blood samples were drawn and peak plasma levels at higher incapacitating doses also holds before the infusion and at 2, 5, 10, 15, 30, and 60 min from the true. Acute autonomic responses to DMT also reached their end of the infusion (45 s after the infusion began). Plasma DMT

highest levels between 2 and 5 min from the end of the infusion, concentration in each sample was then determined using gas usually at the former time point. These included pupil diameter, chromatography-mass spectrometry (GC-MS). A total of nine heart rate, and mean arterial blood pressure.

Frontiers in Pharmacology]] | www.frontiersin.org]]

3

 Article 211]]

![[index-4_1.jpg]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

FIGURE 1 | Structure of a standard two-compartment (plus effect site) pharmacokinetic model with transfer and elimination rates.

At the peak effect time, the drug concentration in the central Clinical observation of the subjects appears to match this compartment is equal to the concentration at the effect site. This time course, with their maximum level of absorption in the makes it straightforward to model the effect site concentration subjective experience occurring at 4–5 min, likely as the initial using the first-order rate equations:

rush and disorientation began to subside. For example, subjects demonstrated seemingly involuntary deep rhythmic breathing, R1E = CTk1e

the mouth being open in a passive regressed manner, and REM-R

like eye movements behind closed lids. Conversely, subjects E0 = CT ke0

appeared to be less under the influence of a high dose of DMT

where R1E is the rate of transfer of the drug from the central as early as 5 min; e.g., moving their fingers, licking their lips or compartment to the effect site and RE0 is the elimination rate yawning, taking a deep sighing breath, and stretching their feet, from the effect site, controlled by the rate constants k1e and suggesting that the acute drug effect was beginning to lighten.

ke0, respectively. The parameters were tuned such that the peak Tellingly, almost every volunteer did not remember the 2 min effect site concentration was reached at ∼3 min. The resulting blood pressure measurement, whereas almost all remembered the simulation is plotted in **Figure 3**]] and seems to fit the observations 5 min measurement, which is when our model suggests the effect well.

site concentration was again approaching ∼60 ng/ml, when exit Typically, the subject would appear to transition into full from the full DMT intoxication occurs.

dissociation from the external world toward the end of the 15 s Having simulated the infusion protocol used in the original saline flush following the 30 s DMT infusion. This suggests that study, we then used the model to develop an infusion protocol

“breakthrough” into the DMT space occurs when the effect site that would bring the effect site concentration smoothly to the concentration reaches ∼60 ng/ml. The subject then remains in predetermined level to ensure “breakthrough” without significant the “space” for the next 6–7 min, with the peak effect occurring overshoot, and to keep the concentration stable indefinitely. A at 3 min, when the effect site concentration is just over 100

100 ng/ml brain concentration was typically achieved during the ng/ml.

most intense period of the DMT experience with a 0.4 mg/kg bolus, and this concentration was chosen as the desired target concentration for the infusion. However, lower or higher concentrations can be achieved using an analogous protocol with TABLE 2 | Fitted pharmacokinetic parameters for 2-compartment model modified infusion rates.

with enzymatic clearance.

We developed our infusion model using the bolus-

Vc (L)

Vp (L)

Km (mg/L)

Vm (mg/min)

Q12 (L/min)

elimination-transfer

(B.E.T.)

methodology,

upon

which

anesthesia infusion protocols are often based (Coetzee, 2012)]]. An 0.4 mg/kg

0.093

0.34

21.48

2.00

0.056

initial bolus, B0, is used to rapidly bring the plasma concentration 0.2 mg/kg

0.14

0.23

9.52

1.07

0.046

to the desired level, CT:

_k_ 12 = _Q_ 12/ _V_ c; _k_ 21 = _Q_ 12/ _V_ p B0 = CTVC

Frontiers in Pharmacology]] | www.frontiersin.org]]

4

 Article 211]]

![[index-5_1.jpg]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

FIGURE 2 | Fitting of two-compartment model with enzymatic clearance to blood sample data. (A) 0.4 mg/kg bolus; (B) 0.2 mg/kg bolus.

The infusion rate is then calculated to equal the sum of the Since the model-fitting established that E is dominated by elimination rate, E, and the transfer rate from the central to the enzymatic clearance, k10 must be reformulated in terms of peripheral compartment, T.

Michaelis-Menten kinetics:

E = VC × k10CT

VmCT

k10CT =

T = VC × k12e−k21tCT

Km + CT

The sum of E and T gives the overall infusion rate as defined This gives the maintenance infusion rate, RT, as:

earlier:

VmCT

R

R

+ C

T = CT × VC

k10 + k12e−k21t

T =

T V

K

Ck12e−k21t

m + CT

Frontiers in Pharmacology]] | www.frontiersin.org]]

5

 Article 211]]



![[index-6_1.jpg]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

FIGURE 3 | Simulated time course of DMT brain concentration following a 0.4 mg/kg bolus.

Since the first term in the RT equation depends only on the bolus produces an effect site concentration of 80 ng/ml; i.e., plasma concentration, it becomes constant when a steady state a breakthrough dose. Once the infusion begins, however, the concentration is reached. The exponential term is only important concentration rises steadily, and reaches 150 ng/ml by the end of before steady state is reached, in the initial stage of the infusion.

the session. This is a very high concentration and is certain to It then decays to zero. Assuming the steady state concentration produce extremely intense effects in almost all individuals.

is the desired effect site concentration, CT, the maintenance Using our PK model, we developed an infusion protocol that infusion rate, Rss, can be calculated:

maintains an effect site concentration of ∼100 ng/ml in a 75 kg subject (**Figure 5**)]]. An initial bolus of 25 mg infused over 30 s VmCT

R

rapidly brings the effect site concentration to just over 100 ng/ml.

ss = Km + CT

Although the plasma concentration spikes at over 200 ng/ml, the desired effect site concentration is reached smoothly with Using the estimated model parameters, this gives a steady state very little overshoot. The infusion begins at 2 min at a rate of infusion rate of 0.93 mg/min. However, during the first few 4.2 mg/min. The infusion is updated every min, and decreases min of the infusion, the exponential term is large; i.e., there according to the peripheral transfer rate decay (the exponential is rapid transfer of drug from the central to the peripheral term in the RT equation). Steady state does not occur until after compartment. This rate of transfer peaks at 3.3 mg/min, at 20 min of infusion, after which a constant maintenance infusion around 2.3 min, before declining rapidly. The infusion rate must rate of 0.93 mg/min is employed.

be set to compensate for this transfer, being decreased gradually The blood sample data used in this work was from a until Rss is reached. This variable infusion rate is essential to previous study (Strassman and Qualls, 1994)]] approved by the attaining and maintaining a stable effect site concentration. If Scientific Advisory Committee of the General Clinical Research the initial rate is too low following the initial bolus, the effect Center (GCRC) and Human Research Review Committee of the site concentration plummets well below that desired and is University of New Mexico School of Medicine, Albuquerque, the not maintained. Conversely, if a high initial infusion rate is New Mexico State Pharmacy Board, the US Drug Enforcement maintained, the effect site concentration continues to increase.

Administration, and the US Food and Drug Administration.

It is possible that this accounts for the relatively high rate Witnessed written informed consent was obtained from all of volunteers dropping out of the Gouzoulis-Mayfrank study subjects, and confidentiality and anonymity were maintained

(Gouzoulis-Mayfrank et al., 2005)]].

throughout the study.

To examine the possibility of effect site concentration overshoot, we performed simulations using the Gouzoulis-Mayfrank infusion protocol: 0.3 mg/kg bolus, followed by an DISCUSSION

infusion beginning at 1.5 min, at a rate of 0.02 mg/kg/min over 84 min. **Figure 4**]] shows the expected effect site concentration The phenomenological content of dream states (Schredl and over this infusion period for a 75 kg subject. The initial Hofmann, 2003; Kahan and Laberge, 2011;]] Thomas et al., 2015)]]

Frontiers in Pharmacology]] | www.frontiersin.org]]

6

 Article 211]]

![[index-7_1.jpg]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

FIGURE 4 | Simulated time course of plasma and effect site DMT concentration using the (Gouzoulis-Mayfrank et al., 2005)]] protocol.

and hallucinations in psychotic disorders have been studied pharmacokinetic and pharmacodynamic properties of DMT are extensively (Jardri et al., 2014;]] Wilkinson, 2014)]], with the aim such that stable effect site concentrations can be achieved using of deepening our understanding of the structure of normal target-controlled infusion. More extensive sampling and more and abnormal states of consciousness. However, whilst the detailed pharmacokinetic modeling are required to establish endogenous human hallucinogen DMT reliably and reproducibly definitive population parameters, the extent of inter- and intra-generates one of the most unusual states of consciousness subject variability, and covariates.

available, its phenomenology has only begun to be characterized.

As with any drug administered by target-controlled infusion, One of the reasons for this is its short duration of action.

subject covariates including weight, age, gender, and liver A technology for extending DMT experiences in a controlled function create significant inter-subject and intra-subject manner beyond what is achievable using bolus administration variability in the dose-concentration response (White et al.,]]

therefore would be of great value.

2008)]]. In this study, the mean coefficients of variation in plasma Modern

target-controlled

infusion

protocols

employ

DMT concentration across the 0.2 and 0.4 mg/kg groups were algorithms that allow the infusion rate to be calculated and 83 and 58%, respectively. Although this variability appears large, adjusted in real time, such that the effect site drug concentration dose-response coefficients of variation between 40 and 60% for can be raised and lowered in order to control, for example, the anesthetic agents (e.g., propofol) administered by bolus injection level of anesthesia (Bailey and Shafer, 1991;]] Shafer and Gregg,]]

are typical. However, the response variability for continuous

1992)]]. Our analysis highlights the potential of using the target-infusion protocols is always lower than that observed for bolus controlled infusion methodology for extended DMT sessions.

injection (Hu et al., 2005)]]. Even with well-established infusion Using time-series blood sampling data and pharmacokinetic protocols, plasma drug concentrations typically deviate 20–30%

modeling, we propose that the unique pharmacological above or below the target concentration (Coetzee et al., 1995)]].

characteristics of DMT make it suitable for administration by For this reason, most anesthesia infusion protocols undergo a target-controlled intravenous infusion. These characteristics number of iterations as pharmacokinetic models are updated include a rapid and short-acting effect, and lack of acute and refined.

tolerance to its subjective effects. Such methods could be used Thus, the variability observed in this initial modeling to control the depth of the experience during a DMT session, study does not preclude the development of a target-moving the subject into more intense levels of DMT intoxication controlled infusion protocol for DMT. In addition, despite or lowering them back into more manageable levels to provide the large dose-concentration variability, the variability in the both respite and easier communication with the research relationship between the dose and the subjective response was team.

much lower. The coefficients of variation of the subjective The methodology developed here is the first step toward a response scores, as measured by the Hallucinogen Rating protocol that is ready for use in research subjects. The purpose Scale, an instrument designed specifically to assess the DMT

of this modeling is to provide a proof-of-principle that the effect, were 46 and 32% for the 0.2 and 0.4 mg/kg groups,

Frontiers in Pharmacology]] | www.frontiersin.org]]

7

 Article 211]]

![[index-8_1.jpg]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

FIGURE 5 | Simulated time course of infusion protocol designed to reach and maintain effect site concentration of ∼100 ng/ml.

respectively (Strassman et al., 1994)]]. This 45% lower subjective what has been previously described in bolus studies. Very high response variability compared to dose-concentration variability acute doses of DMT typically produce a delirium, and users are suggests that a broader target concentration window exists unable to recall details of the experience. However, this may for attainment of the desired subjective effect than might be result from too rapidly attaining supra-maximal concentrations predicted from dose-concentration variability alone. Therefore, of drug. Using the method described here, it may be possible to the target concentration accuracy typically achieved with move the individual gradually into a greater level of intoxication anesthetic agents is likely to be suitable in a DMT infusion while maintaining the characteristic mental clarity associated protocol.

with fully psychedelic doses.

The DMT-containing plant-based decoction ayahuasca In addition, this model is applicable to studies of the neural provides an extended “DMT experience” lasting several correlates of the psychedelic state as revealed by modern hour (Shanon, 2003; Frenopoulo, 2005; Schmidt, 2012)]]. The functional neuroimaging techniques, which are also of great phenomenology of the ayahuasca state has been the subject of interest (Carhart-Harris et al., 2016;]] Speth et al., 2016)]]. Since more extensive analyses than that of pure DMT (Shanon, 2005)]].

such protocols usually require the research subject to be under However, to render the preparation orally-active, the ayahuasca the influence of the drug for an extended period of time, our brew must contain both a DMT-containing plant as well as one methodology would benefit these investigations as well.

containing a beta-carboline MAO inhibitor, such as harmaline Finally, there are potential psychotherapeutic applications.

(McKenna et al., 1984)]]. Since beta-carbolines themselves possess With the resumption of clinical research with psychedelic drugs, psychoactive properties and may potentiate the effects of other projects confirming and extending early research demonstrating psychoactive alkaloids in the plant mixture (Callaway et al.,]]

the benefit of psychedelic drug-assisted psychotherapy are

1999)]], the subjective effects of ayahuasca differ from those of playing a prominent role. The conditions to which these novel pure DMT. Furthermore, it is not possible to precisely regulate treatments are being applied include depression (Berman et al.,]]

and maintain the effect-site DMT concentration with an oral

2000; Aan Het Rot et al., 2010; Buchborn et al., 2014)]], obsessive-preparation.

compulsive disorder (Moreno and Delgado, 1997)]], dysphoric There are a number of research questions that a successful psychological accompaniments of terminal illness (Grof et al.,]]

application of target-controlled IV infusion of DMT may address.

1973; Grob et al., 2011)]], prisoner recidivism (Hendricks For example, the maximum DMT effect may extend further than et al., 2014)]], and substance abuse disorders—including alcohol

Frontiers in Pharmacology]] | www.frontiersin.org]]

8

 Article 211]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

(Bogenschutz et al., 2015)]] and tobacco (Mangini, 1998;]] Krebs population. Using this model, patients could be “titrated” for both and Johansen, 2012)]]. All of the psychedelic substances being the duration and intensity of the DMT state that was most useful used in these studies—LSD, psilocybin, and ayahuasca—exert for augmenting the psychotherapeutic process. For example, in their effects over the course of 6–12 h, consistent with their the case of working through trauma, re-experiencing the feared pharmacokinetic profiles.

stimulus in the altered state might be initiated with induction One of the advantages of the rapid onset and short duration into a mildly altered state of relatively brief duration. In the of intravenous DMT effects is the ability to enter into and exit course of treatment, a more prolonged and intense altered level out of a highly altered state in short order. The therapeutic of consciousness could be applied to a more extensive working potential of this characteristic of DMT was illustrated by an through process, broadening and deepening the therapeutic gains unexpected finding in the DMT tolerance study (Strassman begun with shorter and lighter exposures.

et al., 1996)]]. Normal control volunteers received four fully In summary, we have described the rationale, and presented psychedelic 0.3 mg/kg doses of DMT at 30 min intervals. During the requisite pharmacokinetic calculations, for the development the 10–15 min of relative lucidity between doses, they were quite of target-controlled intravenous infusion of the powerful capable of describing both the effects they had just undergone endogenous psychedelic substance, DMT. The successful as well as what they anticipated would be the effects of the demonstration of this model would provide a valuable tool in subsequent dose(s). The overwhelming effects of a psychedelic determining the role of DMT in normal and altered states of dose of DMT contributed to a heady and dynamic psychological consciousness, and have broad psycho-heuristic, functional confluence of self-disclosure, anticipation, anxiety, vulnerability, imaging, and clinical applicability.

and intimacy. In addition, we found that nearly every subject’s sessions contained an ongoing set of themes, or “storyline.” These themes began with the first dose, evolved over the following two, AUTHOR CONTRIBUTIONS

and resolved and/or culminated in the fourth. The opportunity provided by talking with a therapeutically-trained research team AG performed the analyses. RS provided the original blood during the inter-bolus periods contributed to the psychological sample data. AG and RS wrote the paper.

work that these normal volunteers were able to do. We doubt that this would have been possible if the volunteers were under FUNDING

the influence of the drug unabatedly for that same 2.5 h period.

This paradigm of a continuous target-controlled infusion This work was funded in part by the Okinawa Institute of Science similarly could be turned to therapeutic purposes in a patient and Technology Graduate University, Okinawa, Japan.

REFERENCES

Boszormenyi, Z., and Szara, S. (1958). Dimethyltryptamine experiments with psychotics. J. Mental Sci. 104, 445–453. doi: 10.1192/bjp.104.435.445

Aan Het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Buchborn,

T.,

Schroeder,

H.,

Hoellt,

V.,

and

Grecksch,

G.

(2014).

Charney, D. S., et al. (2010). safety and efficacy of repeated-dose intravenous Repeated lysergic acid diethylamide in an animal model of depression: ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139–145. doi: normalisation of learning behaviour and hippocampal serotonin 5-HT2

10.1016/j.biopsych.2009.08.038

signalling. J. Psychopharmacol. 28, 545–552. doi: 10.1177/02698811145

Absalom, A. R., Glen, J. B., Zwart, G. J. C., Schnider, T. W., and Struys, M. (2016).

31666

Target-controlled infusion: a mature technology. Anesth. Analg. 122, 70–78.

Callaway, J. C., McKenna, D. J., Grob, C. S., Brito, G. S., Raymon, L. P., doi: 10.1213/ANE.0000000000001009

Poland, R. E., et al. (1999). Pharmacokinetics of Hoasca alkaloids in healthy Bailey, J. M., and Shafer, S. L. (1991). A simple analytical solution to the humans. J. Ethnopharmacol. 65, 243–256. doi: 10.1016/S0378-8741(98)0

3-compartment pharmacokinetic model suitable for computer-controlled 0168-8

infusion pumps. IEEE Trans. Biomed. Eng. 38, 522–525. doi: 10.1109/10.81576

Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, Barker, S. A., Mcilhenny, E. H., and Strassman, R. (2012). A critical review A., et al. (2012). Neural correlates of the psychedelic state as determined by of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: fMRI studies with psilocybin. Proc. Natl. Acad. Sci. U.S.A. 109, 2138–2143. doi: 1955-2010. Drug Test. Anal. 4, 617–635. doi: 10.1002/dta.422

10.1073/pnas.1119598109

Barker, S. A., Monti, J. A., and Christian, S. T. (1980). Metabolism of the Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, hallucinogen n,n-dimethyltryptamine in rat-brain homogenates. Biochem.

W., Murphy, K., et al. (2016). Neural correlates of the LSD experience revealed Pharmacol. 29, 1049–1057. doi: 10.1016/0006-2952(80)90169-0

by multimodal neuroimaging. Proc. Natl. Acad. Sci. U.S.A. 113, 4853–4858. doi: Belleville, R. E., Fraser, H. F., Isbell, H., Logan, C. R., and Wikler, A. (1956). Studies 10.1073/pnas.1518377113

on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts Coetzee, J. F. (2012). Principles of intravenous drug infusion. Anaesth. Intensive and development of tolerance during chronic intoxication. AMA. Arch. Neurol.

Care Med. 13, 243–246. doi: 10.1016/j.mpaic.2012.02.011

Psychiatry 76, 468–478. doi: 10.1001/archneurpsyc.1956.02330290012002

Coetzee, J. F., Glen, J. B., Wium, C. A., and Boshoff, L. (1995). Pharmacokinetic Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., model selection for target controlled infusions of propofol - assessment Charney, D. S., et al. (2000). Antidepressant effects of ketamine in of 3 parameter sets. Anesthesiology 82, 1328–1345. doi: 10.1097/00000542-depressed patients. Biol. Psychiatry 47, 351–354. doi: 10.1016/S0006-3223(99)0

199506000-00003

0230-9

Cozzi, N. V., Gopalakrishnan, A., Anderson, L. L., Feih, J. T., Shulgin, A. T., Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P.

Daley, P. F., et al. (2009). Dimethyltryptamine and other hallucinogenic C. R., and Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol tryptamines exhibit substrate behavior at the serotonin uptake transporter and dependence: a proof-of-concept study. J. Psychopharmacol. 29, 289–299. doi: the vesicle monoamine transporter. J. Neural Transm. 116, 1591–1599. doi: 10.1177/0269881114565144

10.1007/s00702-009-0308-8

Frontiers in Pharmacology]] | www.frontiersin.org]]

9

 Article 211]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

Cozzi, N. V., Mavlyutov, T. A., Thompson, M. A., and Ruoho, A. E. (2011).

Nichols, D. E. (2016). Psychedelics. Pharmacol. Rev. 68, 264–355. doi: Indolethylamine N-methyltransferase expression in primate nervous tissue.

10.1124/pr.115.011478

Soc. Neurosci. Abstract Viewer Itinerary Planner 41, 840.19/ZZ71.

Riba, J., Mcilhenny, E. H., Bouso, J. C., and Barker, S. A. (2015). Metabolism Frenopoulo, C. (2005). The ritual use of ayahuasca. J. Psychoactive Drugs 37, and urinary disposition of N,N-dimethyltryptamine after oral and smoked 237–239. doi: 10.1080/02791072.2005.10399807

administration: a comparative study. Drug Test. Anal. 7, 401–406. doi: Gallimore, A. R. (2013). Building alien worlds - the neuropsychological and 10.1002/dta.1685

evolutionary implications of the Astonishing Psychoactive Effects of N,N-Riba, J., Rodriguez-Fornells, A., Urbano, G., Morte, A., Antonijoan, R., Montero, Dimethyltryptamine (DMT). J. Sci. Explor. 27, 455–503.

M., et al. (2001). Subjective effects and tolerability of the South American Gallimore, A. R. (2015). Restructuring consciousness the psychedelic state in psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology light of integrated information theory. Front. Hum. Neurosci. 9:346. doi: 154, 85–95. doi: 10.1007/s002130000606

10.3389/fnhum.2015.00346

Roseman, L., Leech, R., Feilding, A., Nutt, D. J., and Carhart-Harris, R. L.

Gallimore, A. R., and Luke, D. P. (2015). “DMT research from 1956 to the edge (2014). The effects of psilocybin and MDMA on between-network resting state of time,” in Neurotransmissions – An Anthology of Essays on Psychedelics from functional connectivity in healthy volunteers. Front. Hum. Neurosci. 8:204. doi: Breaking Convention, 1st Edn., eds D. King, D. Luke, B. Sessa, C. Adams and A.

10.3389/fnhum.2014.00204

Tollan (London: Strange Attractor Press), 291–316.

Sai-Halasz, A., Brunecker, G., and Szara, S. (1958). Dimethyltryptamine: a new Gambus, P. L., and Troconiz, I. F. (2015). Pharmacokinetic-pharmacodynamic psycho-active drug (unpublished English translation). Psychiatr. Neurol. 135, modelling

in

anaesthesia.

Br.

J.

Clin.

Pharmacol.

79,

72–84.

285–301.

doi: 10.1111/bcp.12286

Sangiah, S., Gomez, M. V., and Domino, E. F. (1979). Accumulation of n,n-Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., dimethyltryptamine in rat-brain cortical slices. Biol. Psychiatry 14, 925–936.

Obradovic, M., et al. (2005). Psychological effects of (S)-ketamine and Schmidt, B. E. (2012). Ayahuasca, ritual, and religion in Brazil. Anthropos 107, N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in 276–277.

healthy volunteers. Pharmacopsychiatry 38, 301–311. doi: 10.1055/s-2005-9

Schredl, M., and Hofmann, F. (2003). Continuity between waking activities 16185

and dream activities. Conscious. Cogn. 12, 298–308. doi: 10.1016/S1053-Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., 8100(02)00072-7

Halberstadt, A. L., et al. (2011). Pilot study of psilocybin treatment for anxiety Shafer, S. L., and Gregg, K. M. (1992). Algorithms to rapidly achieve and in patients with advanced-stage cancer. Arch. Gen. Psychiatry 68, 71–78. doi: maintain stable drug concentrations at the site of drug effect with a computer-10.1001/archgenpsychiatry.2010.116

controlled infusion pump. J. Pharmacokinet. Biopharm. 20, 147–169. doi: Grof, S., Goodman, L. E., Richards, W. A., and Kurland, A. A. (1973). Lsd-assisted 10.1007/BF01070999

psychotherapy in patients with terminal cancer. Int. Pharmacopsychiatry 8, Shanon, B. (2003). Altered states and the study of consciousness - the case of 129–144.

ayahuasca. J. Mind Behav. 24, 125–153.

Hendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., and Shanon, B. (2005). The Antipodes of the Mind - Charting the Phenomenology of the Cropsey, K. L. (2014). Hallucinogen use predicts reduced recidivism among Ayahuasca Experience. Oxford: Oxford University Press.

substance-involved offenders under community corrections supervision.

Sitaram, B. R., Lockett, L., Blackman, G. L., and Mcleod, W. R. (1987). Urinary-J. Psychopharmacol. 28, 62–66. doi: 10.1177/0269881113513851

excretion of 5-methoxy-N,N-dimethyltryptamine, N,N-dimethyltryptamine Hu, C. P., Horstman, D. J., and Shafer, S. L. (2005). Variability of target-controlted and their N-oxides in the rat. Biochem. Pharmacol. 36, 2235–2237. doi: infusion is less than the variability after bolus injection. Anesthesiology 102, 10.1016/0006-2952(87)90159-6

639–645. doi: 10.1097/00000542-200503000-00024

Speth, J., Speth, C., Kaelen, M., Schloerscheidt, A. M., Feilding, A., Jardri, R., Bartels-Velthuis, A. A., Debbane, M., Jenner, J. A., Kelleher, I., Nutt, D. J., et al. (2016). Decreased mental time travel to the past Dauvilliers, Y., et al. (2014). From phenomenology to neurophysiological correlates with default-mode network disintegration under lysergic acid understanding of hallucinations in children and adolescents. Schizophr. Bull.

diethylamide. J. Psychopharmacol. 30, 344–353. doi: 10.1177/02698811166

40, S221–S232. doi: 10.1093/schbul/sbu029

28430

Kahan,

T.

L.,

and

Laberge,

S.

P.

(2011).

Dreaming

and

waking:

Strassman, R. (2001). DMT - The Spirit Molecule. Vermont, VT: Park Street Press.

similarities and differences revisited. Conscious. Cogn. 20, 494–514. doi: Strassman, R. (2008). “The varieties of the DMT experience,” in Inner Paths to 10.1016/j.concog.2010.09.002

Outer Space, 1st Edn., ed R. Strassman (Vermont, VT: Park Street Press), Kenny, G. N. C., and White, M. (1990). A portable computerized infusion system 51–80.

for propofol. Anaesthesia 45, 692–693. doi: 10.1111/j.1365-2044.1990.tb1

Strassman, R. J. (1995). Human psychopharmacology of N,N-dimethyltryptamine.

4416.x

Behav. Brain Res. 73, 121–124. doi: 10.1016/0166-4328(96)00081-2

Krebs, T. S., and Johansen, P. O. (2012). Lysergic acid diethylamide (LSD) for Strassman, R. J., and Qualls, C. R. (1994). Dose-response study of alcoholism: meta-analysis of randomized controlled trials. J. Psychopharmacol.

N,N-dimethyltryptamine

in

humans.1.

Neuroendocrine,

autonomic,

26, 994–1002. doi: 10.1177/0269881112439253

and

cardiovascular

effects.

Arch.

Gen.

Psychiatry

51,

85–97.

doi:

Luke,

D.

(2011).

Discarnate

entities

and

dimethyltryptamine

(DMT):

10.1001/archpsyc.1994.03950020009001

Psychopharmacology, phenomenology and ontology. J. Soc. Psychical Res.

Strassman, R. J., Qualls, C. R., and Berg, L. M. (1996). Differential tolerance 75, 26–42.

to biological and subjective effects of four closely spaced doses of Mangini, M. (1998). Treatment of alcoholism using psychedelic drugs: a N,N-dimethyltryptamine in humans. Biol. Psychiatry 39, 784–795. doi: review of the program of research. J. Psychoactive Drugs 30, 381–418. doi: 10.1016/0006-3223(95)00200-6

10.1080/02791072.1998.10399714

Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., and Kellner, R. (1994). Dose-McKenna, D. J., Towers, G. H. N., and Abbott, F. (1984). Monoamine-oxidase response study of N,N-dimethyltryptamine in humans.2. Subjective effects and inhibitors in south-american hallucinogenic plants - tryptamine and beta-preliminary results of a new rating scale. Arch. Gen. Psychiatry 51, 98–108. doi: carboline constituents of ayahuasca. J. Ethnopharmacol. 10, 195–223. doi: 10.1001/archpsyc.1994.03950020022002

10.1016/0378-8741(84)90003-5

Szara, S. (2007). DMT at fifty. Neuropsychopharmacol. Hungarica 9, 201–205.

Miller, D. R. (1994). Intravenous-infusion anesthesia and delivery devices. Can. J.

Tagliazucchi, E., Carhart-Harris, R., Leech, R., Nutt, D., and Chialvo, D.

Anaesth. 41, 639–652. doi: 10.1007/BF03010006

R. (2014). Enhanced repertoire of brain dynamical states during the Moreno, F. A., and Delgado, P. L. (1997). Hallucinogen-induced relief psychedelic experience. Hum. Brain Mapp. 35, 5442–5456. doi: 10.1002/hbm.

of obsessions and compulsions. Am. J. Psychiatry 154, 1037–1038. doi: 22562

10.1176/ajp.154.7.1037b

Takahashi, T., Takahashi, K., Ido, T., Yanai, K., Iwata, R., Ishiwata, K., et al. (1985).

Mould, D. R., and Upton, R. N. (2012). Basic concepts in population modeling, C-11 labeling of indolealkylamine alkaloids and the comparative-study of their simulation, and model-based drug development. CPT Pharmacometrics Syst.

tissue distributions. Int. J. Appl. Radiat. Isot. 36, 965–969. doi: 10.1016/0020-Pharmacol. 1:e6. doi: 10.1038/psp.2012.4

708X(85)90257-1

Frontiers in Pharmacology]] | www.frontiersin.org]]

10

 Article 211]]

Gal imore and Strassman

Target-Control ed IV DMT Infusion

Thomas, S., Pollak, M., and Kahan, T. L. (2015). Subjective qualities of Yanai, K., Ido, T., Ishiwata, K., Hatazawa, J., Takahashi, T., Iwata, R., et al.

dreams with and without awareness. Dreaming 25, 173–189. doi: 10.1037/

(1986). Invivo kinetics and displacement study of a carbon-11-labeled a0039242

hallucinogen, n,n- c-11 dimethyltryptamine. Eur. J. Nucl. Med. 12, 141–146.

Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., doi: 10.1007/BF00276707

and Angst, J. (1997). Positron emission tomography and fluorodeoxyglucose studies

of

metabolic

hyperfrontality

and

psychopathology

in

the

**Conflict of Interest Statement:** The authors declare that the research was psilocybin model of psychosis. Neuropsychopharmacology 16, 357–372.

conducted in the absence of any commercial or financial relationships that could doi: 10.1016/S0893-133X(96)00246-1

be construed as a potential conflict of interest.

White, M., Kenny, G. N. C., and Schraag, S. (2008). Use of target controlled infusion to derive age and gender covariates for propofol clearance.

Copyright © 2016 Gallimore and Strassman. This is an open-access article Clin. Pharmacokinet. 47, 119–127. doi: 10.2165/00003088-200847020-distributed under the terms of the Creative Commons Attribution License (CC BY).]]

00005

The use, distribution or reproduction in other forums is permitted, provided the Wilkinson, S. (2014). Accounting for the phenomenology and varieties of auditory original author(s) or licensor are credited and that the original publication in this verbal hallucination within a predictive processing framework. Conscious.

journal is cited, in accordance with accepted academic practice. No use, distribution Cogn. 30, 142–155. doi: 10.1016/j.concog.2014.09.002

or reproduction is permitted which does not comply with these terms.

Frontiers in Pharmacology]] | www.frontiersin.org]]

11

 Article 211]]





